Christian Selinger

Dec 25, 2024 | onlinelibrary.wiley.com | Isabel Carbery |Oliver Todd |Christian Selinger

We thank Dai et al. for their interest in our meta-analysis on the prevalence and consequences of frailty in patients with inflammatory bowel disease (IBD) [1, 2]. Our work was a synthesis of 23 observational studies involving 1,893,448 adults [1]. Dai et al. highlighted a single study that did not show an association of frailty with postoperative outcomes [3]. This study was included in our meta-analysis.

Dec 6, 2024 | mdpi.com | Kassem Sharif |Konstantina Rosiou |Michael Rennie |Christian Selinger

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Aug 10, 2024 | mdpi.com | Christian Selinger |van der Meulen

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Aug 1, 2024 | gut.bmj.com | Christian Selinger

INFLAMMATORY BOWEL DISEASEDespite major scientific discoveries, our understanding of the causes of IBD remains rather incomplete.

Apr 7, 2024 | bpno.dk | Christian Selinger

april 2024 In this MEDtalk, Dr. Christian Selinger presents a systematic review that his research group conducted into reproductive safety issues of novel small molecules for the treatment of inflammatory bowel disease. The study aimed to describe the reproductive outcomes of the JAK inhibitors tofacitinib, filgotinib, and upadacitinib and the S1P inhibitor ozanimod regarding their effects on pregnancy outcomes.